Consensus

EAS Consensus Position Paper Initiative

The EAS Consensus Panel, comprised of internationally renowned experts in atherosclerosis and cardiovascular disease, was first convened in November 2009 to consider the evidence for non-LDL lipids as risk factors for cardiovascular disease.  To 2020 the Panel was co-chaired by Professor John Chapman (France), Professor Henry N. Ginsberg (USA), and Professor Alberico L. Catapano (Italy). 

From 2021 a new structure for the EAS Consensus Panel has been created, with coordination by Professor Alberico Catapano, Professor Lale Tokgözoğlu (Turkey) and Professor Kausik Ray (Imperial College London, UK). For each position paper topic, two or more independent chairs are appointed. These then drive the focus and content together with experts from around the world with the relevant expertise in that topic.

Publications by the Consensus Panel

Listed in order of publication year, most recent, first.

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease—European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force 
Taking action: European Atherosclerosis Society targets the United Nations Sustainable Development Goals 2030 Agenda to fight atherosclerotic cardiovascular disease in Europe
Low-density lipoproteins cause atherosclerotic cardiovascular disease; pathophysiological, genetic and therapeutic insights. A consensus statement from the European Atherosclerosis Society Consensus Panel.

Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM.

Rare Dyslipidaemias: From Phenotype to Genotype to Management. A European Atherosclerosis Society Task Force Consensus Statement.
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.
Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. A joint consensus statement from the European Society of Cardiology and the European Atherosclerosis Society Task Force.
2017 Update of ESC/EAS Task force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia.
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. 
ESC/EAS Task Force issues updated clinical guidance for the use of PCSK9 inhibitors.
Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points. A joint consensus statement from the EAS and EFLM. 
Familial Hypercholesterolaemia in children and adolescents: gaining decades of life by optimising detection and treatment. Consensus Statement of the European Atherosclerosis Society.
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Consensus Statement of the European Atherosclerosis Society.
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. Consensus Statement of the European Atherosclerosis Society. 
Consensus Position Paper on plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Consensus Statement of the European Atherosclerosis Society. 
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Consensus Statement of the European Atherosclerosis Society.
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus Statement of the European Atherosclerosis Society. 
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Consensus Statement of the European Atherosclerosis Society.
Lipoprotein(a) as a cardiovascular risk factor: current status. Consensus Statement of the European Atherosclerosis Society.